As reported in MDJ Online, Piedmont Transplant Institute (part of Piedmont Atlanta Hotel) represents one of six research sites in the U.S. for the potentially groundbreaking Pro-Act Study. The study has been made possible by pharmacological advances that have achieved cure rates of greater than 95% for the Hepatitis C virus (HCV). In the study, patients who do not have HCV and are on the waiting list for either kidney or liver transplants receive organs from donors who are HCV-positive. Those patients are then treated for HCV shortly after transplant to try to prevent the complications associated with Hepatitis C. The goal is to create a larger potential pool of organs for those in desperate need—a development that could prove to be life-saving.
The study, the formal name of which is “Prevention of De Novo HCV with Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant,” is being run out of the University of California-San Francisco. Piedmont Transplant Institute is the data-monitoring site for the study. Raymond A. Rubin, M.D., chief scientific officer and transplant hepatologist at Piedmont Transplant Institute, wrote the study’s protocol.
Follow the link to MDJ Online for additional information.